Echinacea Tablet, Orally Disintegrating
NDC Package 60986-2020-2
Package Information
Echinacea (echinacea angustifolia, hamammelis virginiana, calcarea phosphorica, hydrastis canadanesis, senega officinalis, silicea, conium, aurum muriaticum natronatum, calcarea carbonica, fucus vesiculosus, lachesis mutus) tablets is a medication used as FOR TEMPORARY RELIEF OF SORE THROATS AND LYMPHATIC INFLAMMATION. This formulation utilizes a tablet, orally disintegrating delivery system. Marketed by Marco Pharma International Llc., this product is identified by NDC 60986-2020.
Identification & Billing
Clinical Specifications
- CONIUM MACULATUM FLOWERING TOP 4 [hp_X]/1
- ECHINACEA ANGUSTIFOLIA 1 [hp_X]/1
- FUCUS VESICULOSUS 5 [hp_X]/1
- GOLDENSEAL 4 [hp_X]/1
- HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK 2 [hp_X]/1
- LACHESIS MUTA VENOM 8 [hp_X]/1
- OYSTER SHELL CALCIUM CARBONATE, CRUDE 5 [hp_X]/1
- POLYGALA SENEGA ROOT 4 [hp_X]/1
- SILICON DIOXIDE 4 [hp_X]/1
- SODIUM TETRACHLOROAURATE 5 [hp_X]/1
- TRIBASIC CALCIUM PHOSPHATE 3 [hp_X]/1
Regulatory & Marketing
Hierarchy Structure
- 60986 - Marco Pharma International Llc.
- 60986-2020 - Echinacea
- 60986-2020-2 - 100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC
- 60986-2020 - Echinacea
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 60986-2020-2 identifies a specific commercial package of 100 tablet, orally disintegrating in 1 bottle, plastic of Echinacea, a human over the counter drug labeled by Marco Pharma International Llc.. This tablet, orally disintegrating is formulated for oral use and contains conium maculatum flowering top; echinacea angustifolia; fucus vesiculosus; goldenseal; hamamelis virginiana root bark/stem bark; lachesis muta venom; oyster shell calcium carbonate, crude; polygala senega root; silicon dioxide; sodium tetrachloroaurate; tribasic calcium phosphate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Marco Pharma International Llc. on March 01, 1992. The current certification is valid through December 31, 2027.
How is this Marco Pharma International Llc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 60986202002. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.